• Anticoagulants study shows lower risk of major bleeds pharmaceutical-technology
    July 12, 2018
    The University of Nottingham’s Division of Primary Care investigated the risks and benefits of the three most common types of direct anti-coagulants (DOACs), apixaban, dabigatran and rivaroxaban, compared with the current main treatment warfarin for patie
PharmaSources Customer Service